NEW YORK (Reuters Health)—Results from a substantial proportion of large, registered, randomized controlled trials (RCTs) can go unpublished for years after their completion, researchers report. “These unpublished and unreported trials include a vast number of patients, about 90,000,” Dr. John P. A. Ioannidis from Stanford University in California told Reuters Health. “Many people think that…
Search results for: treat-to-target

Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
Although antimitochondrial antibodies are present in SLE patients, researchers have has difficulty investigating the phenomenon due to barriers in isolating pure mitochondria. The study describes a technique that allows for such an investigation and provides insight into how the adaptive immune system recognizes mitochondrial organelles…

The RISE Registry Delivers Practice-Based Evidence to Rheumatologists
The advent of quality-based healthcare, such as the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), requires rheumatology professionals to demonstrate their practice is based on interventions supported by the best available evidence and that their practice, in turn, provides quality care. These requirements have increased the need for methods to measure and quantify…

MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA
New research does not support the use of a magnetic resonance imaging (MRI)-guided strategy for treating RA patients. The study found that among RA patients in remission, an MRI-guided treat-to-target strategy compared with a conventional treat-to-target strategy did not result in improved disease activity remission rates or reduced radiographic progression…

The RISE Registry: A Powerful Collaboration Tool for Clinicians & Researchers
Practice-based evidence, like that in the RISE registry, can be used to describe trends in patient care, look at comparative effectiveness of interventions and much more.

Destructive Arthritis: From Prevention to Progression to Remission
CHICAGO—Josef S. Smolen, MD, professor of internal medicine and chair of the Department of Rheumatology, Vienna General Hospital, Austria, presented the prestigious Paul Klemperer, MD, Memorial Lecture at the 2018 ACR/ARHP Annual Meeting. Dr. Smolen, whose work is frequently cited, created the treat-to-target strategy for rheumatoid arthritis (RA). Dr. Smolen began by noting a simple…

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?
Results of a recent study in Arthritis & Rheumatology fail to clarify whether urate-lowering therapies may potentially reduce mortality risk in patients with gout.1 The study also underscores the fact that many physicians are not following the ACR guideline to help their patients achieve target serum urate levels. Partly because of this, it remains unclear…

The Effects of Early RA Treatment on CVD
New research exploring the effects of etanercept on cardiovascular disease in treatment-naive, early RA patients suggests a treatment advantage with etanercept, a TNF inhibitor and methotrexate over treatment with methotrexate and a conventional synthetic disease-modifying anti-rheumatic drug…

The 2018 ARHP Merit Awards & ACR Distinguished Fellows
CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARHP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find interviews…

AFLAR Experts Discuss Highlights, Hurdles in Rheumatology in Africa
CHICAGO—Rheumatology physicians and researchers from Africa said the field’s resources and medical literature on the continent are slowly expanding, but they repeatedly lamented that the millions who suffer from rheumatic diseases there have major obstacles to overcome to access care. Their reviews and assessments—sometimes grim and sometimes hopeful—came in a session that was a joint…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 18
- Next Page »